Diferencia entre revisiones de «Verapamil»
(Switch SMW query from broadtable to table format for better layout with TOC) |
|||
| (No se muestran 4 ediciones intermedias de 3 usuarios) | |||
| Línea 16: | Línea 16: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Category C, verapapmil crosses the placenta and can cause adverse fetal effects such as heart block, hypotension, and bradycardia | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Present in breast milk with relative infant dose of <1% which is considered safe for the infant. | ||
*Renal dosing: | *Renal dosing: Can accumulate causing increased effects, monitor closely and consider lowering dose. | ||
*Hepatic dosing: 20-50% of normal dose | *Hepatic dosing: 20-50% of normal dose | ||
| Línea 48: | Línea 48: | ||
*Reduces systemic vascular resistance, vasodiolates peripheral arteries | *Reduces systemic vascular resistance, vasodiolates peripheral arteries | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Verapamil]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
| Línea 54: | Línea 71: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] | |||
Revisión actual - 21:57 20 mar 2026
Administration
- Type: Calcium channel blocker
- Dosage Forms:
- Routes of Administration: IV, PO
- Common Trade Names:
Adult Dosing
- Atrial fibrillation, paroxysmal SVT
- IV: 5-10mg (0.075-0.15 mg/kg), may give an initial 10mg IV after 30 minutes if inadequate response
- PO: 240-48 mg daily in 3-4 divided doses
- Angina, hypertension: 80-120mg PO 3 times per day
Pediatric Dosing
- Afib/flutter, SVT
- IV 0.1-0.2 (<1yo) or 0.1-0.3 (>1yo) mg/kg. Repeat after 30 minutes if inadequate response
- PO: 4-10 mg/kg/day in 3 divided doses
Special Populations
- Pregnancy Rating: Category C, verapapmil crosses the placenta and can cause adverse fetal effects such as heart block, hypotension, and bradycardia
- Lactation risk: Present in breast milk with relative infant dose of <1% which is considered safe for the infant.
- Renal dosing: Can accumulate causing increased effects, monitor closely and consider lowering dose.
- Hepatic dosing: 20-50% of normal dose
Contraindications
- Allergy to class/drug
- Afib/flutter associated with accessory bypass tract, e.g. WPW, Lown-Ganong-Levine syndrome
- Cardiogenic shock, hypotension, EF <30%
- 2nd or 3rd degree AV block, sick sinus syndrome
Adverse Reactions
Serious
Common
- Hypotension
- Edema
- URI or flu-like symptoms
- Dizziness, headache
- Constipation
Pharmacology
- Half-life: 4-20 hours
- Metabolism: Hepatic- P450 CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18
- Excretion: Renal primarily. Not dialyzable
Mechanism of Action
- Inhibits L-type (slow) calcium channels, blocking influx of calcium into myocardial cells
- Reduces systemic vascular resistance, vasodiolates peripheral arteries
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Paroxysmal supraventricular tachycardia | 1-4 mg/kg PO q8h (pediatric, >12 months only) | Calcium-channel blocker (pediatric >12 months) | PO | Pediatric |